PIK3CA and breast cancer: Further studies on the use of alpelisib to treat HER2+ BC are ongoing, including the EPIK-B2 trial, which is assessing the combination of alpelisib with trastuzumab and pertuzumab as maintenance therapy in patients with HER2+ ABC harboring PIK3CA mutations [150].